Antihypertensive drugs, dietary salt, and renal protection: How low should you go and with which therapy?

American Journal of Kidney Diseases

Volumn 32, Issue 1, 1998, Pages 1-22

  Weir, Matthew R ^a   Dworkin, Lance D ^b  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^b NONE

Author keywords

Blood pressure; Renal protection; Salt

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SODIUM CHLORIDE;

CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; CREATININE CLEARANCE; DISEASE COURSE; ESSENTIAL HYPERTENSION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; KIDNEY TUBULE PRESSURE; REVIEW; SALT INTAKE; SYSTOLIC BLOOD PRESSURE;

EID: 0031863614     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.1998.v32.pm9669419     Document Type: Article

References (111)

1. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J: Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet 335:765-774, 1990
2. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 265:3255-3264, 1991
3. National High Blood Pressure Education Program Group: 1995 update of the working group reports on chronic renal failure and renovascular hypertension. Arch Intern Med 156:1938-1947, 1996
4. Brenner BM: Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int 23:647-655, 1983
5. Anderson S, Meyer T, Rennke HG, Brenner BM: Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 76:612-619, 1985
6. Kakinuma Y, Kawamura T, Bills T, Yoshioka T, Ichikawa I, Fogo A: Blood pressure independent effect of angiotensin inhibition on the glomerular and non-glomerular vascular lesions of chronic renal failure. Kidney Int 42:46-55, 1996
7. Dworkin LD, Grosser M, Feiner HD, Ullian M, Parker M: Renal vascular effects of antihypertensive therapy in uninephrectomized spontaneously hypertensive rats. Kidney Int 35:790-798, 1989
8. Neugarten J, Kaminetsky B, Feiner H, Schacht RG, Liu DT, Baldwin DS: Nephrotoxic serum nephritis with hypertension: Amelioration by antihypertensive therapy. Kidney Int 28:135-139, 1985
9. Dworkin LD, Feiner HD, Randazzo J: Glomerular hypertension and injury in desoxycorticosterone-salt rats on antihypertensive therapy. Kidney Int 31:718-724, 1987
10. Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension. J Clin Invest 77:1993-2000, 1986
11. Yoshida Y, Kawamura T, Ikoma M, Fogo A, Ichikawa I: Effects of antihypertensive drugs on glomerular morphology. Kidney Int 36:626-635, 1989
12. Dworkin LD, Brenner BM: The renal circulations, in Brenner BM, Rector F (eds): The Kidney, Philadelphia, PA, Saunders, 1996, pp 247-285
13. Parati G, Omboni S, DiRienzo M, Frattola A, Albini F, Mancia G: Twenty-four hour blood pressure variability: Clinical implications. Kidney Int 41:S24-S28, 1992 (suppl 37)
14. Griffen KA, Picken M, Bidani AK: Radiotelemetric BP monitoring, antihypertensives and glomeruloprotection in remnant kidney model. Kidney Int 46:1010-1018, 1994
15. Dworkin LD, Feiner HD, Parker M, Tolbert E: Effects of nifedipine and enalapril on glomerular structure and function in uninephrectomized spontaneously hypertensive rats. Kidney Int 39:1112-1117, 1991
16. Dworkin LD, Tolbert E, Recht PA, Hersch JC, Feiner H, Levin RI: Effects of amlodipine on glomerular filtration, growth, and injury in experimental hypertension. Hypertension 27:245-250, 1996
17. Reams GP, Villarreal D, Wu Z, Wang X, Luger AM, Bauer JH: An evaluation of the renal protective effect of manidipine in the uninephrectomized spontaneously hypertensive rat. Am Heart J 125:620-625, 1993
18. Griffen KA, Picken MM, Bidani AK: Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys. J Clin Invest 96:793-800, 1995
19. Bidani AK, Schwartz MM, Lewis EJ: Renal autoregulation and vulnerability to hypertensive injury in remnant kidney. Am J Physiol 252:F1003-F1010, 1987
20. Ikoma M, Kawamura T, Kakinuma Y, Fogo A, Ichikawa I: Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. Kidney Int 40:195-202, 1991
21. Kon V, Fogo A, Ichikawa I: Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 44:545-550, 1993
22. Klahr S, Schriener G, Ichikawa I: The progression of renal disease. N Engl J Med 318:1657-1666, 1988
23. Dworkin LD, Benstein JA, Parker M, Tolbert E, Feiner HD: Calcium antagonists and converting enzyme inhibitors reduce renal injury in rats with remnant kidneys by different mechanisms. Kidney Int 43:808-814, 1993
24. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure: The fifth report of the Joint Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 153:154-183, 1993
25. Shemin D, Dworkin LD: Sodium balance in renal failure. Curr Opin Nephrol Hypertens 6:128-132, 1997
26. Blythe WB: Natural history of hypertension in renal parenchymal disease. Am J Kidney Dis 6:A50-A56, 1985
27. Flack JM, Ensrud KE, Mascioli S, Launer CA, Svendsen K, Elmer PJ, Grimm RH Jr: Racial and ethnic modifiers of the salt-blood pressure response. Hypertension 17:I115-I121, 1991 (suppl)
28. Bakris GL, Weir MR: Salt intake and reductions in arterial pressure and proteinuria. Am J Hypertens 9:200S-206S, 1996
29. Benstein JA, Parker M, Feiner HD, Dworkin LD: Superiority of salt restriction over diuretics in reducing renal hypertrophy and injury in uninephrectomized SHR. Am J Physiol 258:F1675-1681, 1990
30. Lax DS, Benstein JA, Tolbert E, Dworkin LD: Effects of salt restriction on renal growth and glomerular injury in rats with remnant kidneys. Kidney Int 41:1527-1534, 1992
31. Dworkin LD, Benstein JA, Tolbert E, Feiner HD: Salt restriction inhibits renal growth and stabilizes injury in rats with established renal disease. J Am Soc Nephrol 7:437-442, 1996
32. Daniels BS, Hostetter TH: Adverse effects of growth in the glomerular microcirculation. Am J Physiol 258:F1409-F1416, 1990
33. Klag MJ, Whelton PK, Randall BL, Neaton JD, Braucati FL, Ford CE, Shulman NB, Stamler J: Blood pressure and end-stage renal disease in men. N Engl J Med 334:13-18, 1996
34. Walker GW, Neaton JD, Cutler JA, Neuwirth R, Cohen JD, for the MRFIT Research Group: Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial: Racial and treatment effects. JAMA 268:3085-3091, 1992
35. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, Schneider KA: Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 13:80-93, 1989 (suppl 1)
36. Tierney WM, Harris LE, Copley JB, Luft FC: Effect of hypertension and type II diabetes on renal function in an urban population. Am J Hypertens 3:69-75, 1990
37. Perry HM Jr, Miller JP, Fornoff JR, Baty JD, Sambhi MP, Rutan G, Moskowitz DW, Carmody SE: Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 25:587-594, 1995
38. Brazy PC, Fitzwilliam JF: Progressive renal disease: Role of race and antihypertensive medications. Kidney Int 37:1113-1119, 1990
39. Locatelli F, Marcelli D, Comelli M, Alberti D, Graziani G, Buccianti G, Redaelli B, Giangrande A: Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Nephrol Dial Transplant 11:461-467, 1996
40. Rostand SG, Brown G, Kirk KA, Rutsky EA, Dustan HP: Renal insufficiency in treated essential hypertension. N Engl J Med 320:684-688, 1989
41. Rosansky SJ, Hoover DR, King L, Gibson J: The association of blood pressure levels and change in renal function in hypertensive and nonhypertensive subjects. Arch Intern Med 150:2073-2076, 1990
42. Madhavan S, Stockwell D, Cohen H, Alderman MH: Renal function during antihypertensive treatment. Lancet 345:749-751, 1995
43. Weir MR, Tuck ML: Essential hypertension in blacks: Is it a metabolic disorder? Am J Kidney Dis 21:58-67, 1993 (suppl 1)
44. Weir MR: Salt intake and hypertensive renal injury in African-Americans: A therapeutic perspective. Am J Hypertens 8:635-644, 1995
45. Weir MR, Hanes DS: Hypertension in African-Americans: A paradigm of metabolic disarray. Semin Nephrol 16:102-109, 1996
46. Brancati FL, Whittle JC, Whelton PK, Seidler AJ, Klag MJ: The excess incidence of diabetic end-stage renal disease among blacks: A population-based study of potential explanatory factors. JAMA 268:3079-3084, 1992
47. Freedman BI, Spray BJ, Tuttle AB, Buckalew VM: The familial risk of end-stage renal disease in African-Americans. Am J Kidney Dis 21:387-393, 1993
48. Perneger TV, Whelton PK, Klag MJ: Race and end-stage renal disease: Socioeconomic status and access to health care as mediating factors. Arch Intern Med 155:1201-1208, 1995
49. Schmitz PG, Kasiske BL, O'Donnell MP, Keane WF: Lipids and progressive renal injury. Semin Nephrol 9:354-369, 1989
50. Rosansky SJ, Hoover DR, King L, Gibson J: The association of blood pressure levels and change in renal function in hypertensive and nonhypertensive subjects. Arch Intern Med 150:2073-2076, 1990
51. Brazy PC, Stead WW, Fitzwilliam JF: Progression of renal insufficiency: Role of blood pressure. Kidney Int 35:670-674, 1989
52. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330:877-884, 1994
53. Modification of Diet in Renal Disease Study Group, Hebert LA, Kusek JW, Greene T, Agodoa LY, Jones CA, Levey AS, Breyer JA, Faubert P, Rolin HA, Wang S-R, Writing Group: Effects of blood pressure control on progressive renal disease in blacks and whites. Hypertension 30:428-435, 1997
54. Toto RD, Mitchell HC, Smith RD, Lee HC, McIntire D, Pettinger WA: "Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int 48:851-859, 1995
55. Wright JT, Kusek JW, Toto RD, Lee JY, Agodoa LY, Randall OS, Kirk KA, Glassock R: Design and baseline characteristics of participants in the African-American Study of Kidney Disease and Hypertension (AASK) pilot study. Control Clin Trials 17:3S-16S, 1996(suppl 4)
56. Hebert LA, Bain RP, Verme D, Cattran D, Whittier FC, Tolchin N, Rohde RD, Lewis EJ: Remission of nephrotic range proteinuria in type I diabetes. Collaborative Study Group. Kidney Int 46:1688-1693, 1994
57. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S: Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 50:1641-1650, 1996
58. Rydel JJ, Korbet SM, Borok RZ, Schwartz MM: Focal segmental glomerular sclerosis in adults: Presentation, course, and response to treatment. Am J Kidney Dis 25:534-542, 1995
59. Pei Y, Cattran D, Greenwood C: Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int 42:960-966, 1992
60. Neelakantappa K, Gallo G, Baldwin DS: Proteinuria in IgA nephropathy. Kidney Int 33:716-721, 1988
61. Narvarte J, Prive M, Saba SR, Ramirez G: Proteinuria in hypertension. Am J Kidney Dis 10:408-416, 1987
62. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL: Blood pressure, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 123:754-762, 1995
63. Parving HH: The impact of hypertension and antihypertensive treatment on the course and prognosis of diabetic nephropathy. J Hypertens 8:S187-S191, 1990 (suppl 7)
64. Mathiesen ER, Hommel E, Giese J, Parving HH: Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 303:81-87, 1991
65. Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WM: Effects of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Intern Med 118:129-138, 1993
66. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462, 1993
67. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert -T: Diabetic nephropathy in type 1 (insulin-dependent) diabetes: An epidemiological study. Diabetologia 25:496-501, 1983
68. Knowles HC Jr: Long term juvenile diabetes treated with unmeasured diet. Trans Assoc Am Phys 84:95-101, 1971
69. Parving HH, Hommel E, Mathiesen E, Skott P, Edsberg B, Bahnsen M, Lauritzen M, Hougaard P, Lauritzen E: Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. BMJ 296:156-160, 1988
70. Parving HH, Andersen AR, Smidt UM, Oxenboll B, Edsberg B, Christiansen JS: Diabetic nephropathy and arterial hypertension. Diabetologia 24:10-12, 1983
71. Schmitz A, Pedersen MM, Hansen KW: Blood pressure by 24 h ambulatory recordings in type 2 (non-insulin dependent) diabetics. Relationship to urinary albumin excretion. Diabetes Metab 17:301-307, 1991
72. Christensen CK: Abnormal albumin and blood pressure rise in incipient diabetic nephropathy induced by exercise. Kidney Int 25:819-823, 1984
73. Rossing P, Hommel E, Smidt UM, Parving HH: Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes 42:715-719, 1993
74. Mogensen CE: Progression of nephropathy in long-term diabetics with proteinuria and effect of initial antihypertensive treatment. Scand J Clin Lab Invest 36:383-388, 1976
75. Parving HH, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA: Effect of antihypertensive treatment on kidney function in diabetic function in diabetic nephropathy. BMJ 294:1443-1447, 1987
76. Bjorck S, Mulec H, Johnsen SA, Norden G, Aurell M: Renal protective effect of enalapril in diabetic nephropathy. BMJ 304:339-343, 1992
77. Dillon JJ: The quantitative relationship between treated blood pressure and progression of diabetic renal disease. Am J Kidney Dis 22:798-802, 1993
78. Guyton AC, Langsten JB, Navar G: Theory for renal autoregulation by feedback at the juxtaglomerular apparatus. Circ Res 14/15:I-187-I-197, 1964(suppl 1)
79. Guyton AC, Coleman TG, Cowley AV Jr, Scheel KW, Manning RD Jr, Norman RA Jr: Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med 52:584-594, 1972
80. Hall JE, Guyton AC: Control of sodium excretion and arterial pressure by intrarenal mechanisms and the reninangiotensin system, in Laragh JH, Brenner BM teds): Hypertension: Pathophysiology, Diagnosis and Management. New York, NY, Raven, 1990, pp 1105-1130
81. Campese VM, Parise M, Karubian F, Bigazzi R: Abnormal renal hemodynamics in black salt-sensitive patients with hypertension. Hypertension 18:805-812, 1991
82. Weir MR, Dengel DR, Behrens MT, Goldberg AP: Salt-induced increases in systolic blood pressure affect renal hemodynamics. Hypertension 25:1339-1344, 1995
83. van Paassen P, de Zeeuw D, Navis G, de Jong P: Does the renin-angiotensin system determine the renal and systemic hemodynamic response to sodium in patients with essential hypertension? Hypertension 27:202-208, 1996
84. Weir MR: Insulin resistance and salt sensitivity. A renal hemodynamic abnormality? Am J Hypertens 9:193s-199s, 1996
85. Bigazzi R, Bianchi S, Baldari D, Sgherri G, Baldari G, Campese VM: Microalbuminuria in salt-sensitive patients. A marker for renal and cardiovascular risk factors. Hypertension 23:195-199, 1994
86. Bigazzi R, Bianchi S, Baldari G, Campese V: Clustering of cardiovascular risk factors in salt-sensitive patients with essential hypertension: Role of insulin. Am J Hypertens 9:24-32, 1995
87. Campese VM: Salt sensitivity in hypertension. Renal and cardiovascular implications. Hypertension 23:531-550, 1994
88. Kannel WB, Stampfer MJ, Castelli WR Verier J: The prognostic significance of proteinuria: The Framingham study. Am Heart J 108:1347-1352, 1984
89. Samuelsson O, Wilhelmsen L, Elmfeldt D, Pennert K, Wedel H, Wikstrand J, Berglund G: Predictors of cardiovascular morbidity in treated hypertension: Results from the primary preventive trial in Goteborg, Sweden. J Hypertens 3:167-176, 1985
90. Bakris GL: Microalbuminuria: Prognostic implications. Curr Opin Nephrol Hypertens 5:219-223, 1996
91. Abbott KC, Sanders LR, Bakris GL: Microalbuminuria in non-insulin-dependent diabetes mellitus: Implications for renal survival. Arch Intern Med 154:146-153, 1994
92. Strojek K, Grzeszczak W, Lacha B, Gorska J, Keller CK, Ritz E: Increased prevalence of salt sensitivity of blood pressure in IDDM with and without microalbuminuria. Diabetologia 38:1443-1448, 1995
93. Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D: Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 36:272-280, 1989
94. Bakris GL, Smith AC: Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Ann Intern Med 125:201-204, 1996
95. Weir MR: The influence of dietary salt on the antiproteinuric effect of calcium channel blockers. Am J Kidney Dis 29:800-805, 1997
96. Maki DD, Ma JZ, Louis TA, Kasiske BL: Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 155:1073-1080, 1995
97. Whelton PK, He J, Cutler JA, et al: Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. JAMA 277:1624-1632, 1997
98. Gruppo Italiano di Studi Epidemiologici in Nefrologia: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857-1863, 1997
99. Ruilope LM, Miranda B, Morales JM, Rodicio JL, Romero JC, Raij L: Converting enzyme inhibition in chronic renal failure. Am J Kidney Dis 13:120-126, 1989
100. Zucchelli P, Zuccala A, Borghi M, Fusaroli M, Sasdelli M, Stallone C, Sanna G, Gaggi R: Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 42:452-458, 1992
101. Kamper AL, Strandgaard S, Leyssac PP: Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial. Am J Hypertens 5:423-430, 1992
102. Hannedouche T, Landais P, Goldfarb B, el Esper N, Foumier A, Godin M, Durand D, Chanard J, Mignon F, Suo JM: Randomized controlled trial of enalapril and beta-blockers in non-diabetic chronic renal failure. BMJ 309:833-837, 1994
103. Liou HH, Huang TP, Campese VM: Effect of long-term therapy with captopril on proteinuria and renal function in patients with non-insulin-dependent diabetes and with non-diabetic renal diseases. Nephron 69:41-48, 1995
104. Ihle BU, Whitworth JA, Shahinfar S, Cnaan A, Kincaid-Smith PS, Becker GJ: Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: A controlled double-blind trial. Am J Kidney Dis 27:489-495, 1996
105. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M, Ponticelli C, Ritz E, Zucchelli P and the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Group: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of renal insufficiency. N Engl J Med 334:939-945, 1996
106. Giatras I, Lau J, Levey AS, for the Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Dis-ease Study Group: Effect of angiotensin-converting-enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials. Ann Intern Med 127:337345, 1997
107. Harris DCH, Hammond WS, Burke TJ, Schrier RW: Verapamil protects against progression of experimental chronic renal failure. Kidney Int 31:41-46, 1987
108. Weir MR: Angiotensin-II receptor antagonists: A new class of antihypertensive agents. Am Fam Physician 53:589-594, 1996
109. Gansevoort RT, de Zeeuw D, Shahinfar S, Redfield A, de Jong PE: Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens 12:S37-S42, 1994 (suppl 2)
110. Ichikawa I: Will angiotensin II receptor antagonists be renoprotective in humans? Kidney Int 50:684-692, 1996
111. Lazarus JM, Bourgoignie JJ, Buckalew VM, Greene T, Levey AS, Milas NC, Paranandi L, Peterson JC, Porush JG, Rauch S, Soucie JM, Stollar C: Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. Hypertension 29:641-650, 1997